News
Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
CVS Health’s insurance division Aetna will stop offering plans for individuals on the Affordable Care Act exchanges in 2026, after the company projected big losses in the business this year.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark ... its NovoCare online pharmacy. Under the deals, Hims & Hers is offering a $599 bundled monthly ...
CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...
CNBC on MSN8d
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominanceEli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Boosted by Microsoft's offerings, CVS intends to accelerate ... Expanding digital means CVS plans to improve its omnichannel pharmacy capabilities using Microsoft tools to provide personalised ...
President Trump’s executive order provides a framework for tying the prices of U.S. pharmaceutical products to the lower ...
UnitedHealth Group Incorporated's stock faces a steep decline amid leadership turmoil, regulatory pressures, and rising costs ...
Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to ... how much the CVS formulary change will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results